Medpace Holdings (MEDP) Cost of Revenue (2015 - 2026)

Medpace Holdings (MEDP) has reported Cost of Revenue for 12 consecutive years, with $510.3 million the latest figure, recorded in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $510.3 million, up 34.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 28.61% YoY), and the FY2025 annual result was $1.8 billion, up 21.81% from the prior year.
• Cost of Revenue was $510.3 million for Q1 2026 at Medpace Holdings, up from $503.1 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $510.3 million in Q1 2026 and troughed at $232.3 million in Q1 2022.
• Average Cost of Revenue over 5 years is $360.1 million, with a median of $359.3 million recorded in 2023.
• Year-over-year, Cost of Revenue retreated 0.92% in 2024 and soared 40.43% in 2025.
• Over 5 years, Cost of Revenue stood at $278.4 million in 2022, then increased by 29.9% to $361.6 million in 2023, then retreated by 0.92% to $358.3 million in 2024, then jumped by 40.43% to $503.1 million in 2025, then increased by 1.42% to $510.3 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $510.3 million in Q1 2026, $503.1 million in Q4 2025, and $463.0 million in Q3 2025.